A synthetic analog of the immunomodulatory tetrapeptide tuftsin, stabilised with a Pro-Gly-Pro extension. Proposed anxiolytic activity via modulation of GABA-A receptor expression, inhibition of enkephalin degradation, and effects on serotonergic tone — reportedly without the sedation, dependence, or withdrawal associated with benzodiazepines.
As with Semax: developed and studied in Russia, registered there for anxiety disorders, with a trial literature that is largely Russian-language and not independently replicated or reviewed by Western regulators.
Not FDA-approved. Registered as a medicine in Russia. Not lawfully marketed for human use in the US.
Reported tolerability is favourable in the Russian literature; independent verification is lacking. Long-term data unavailable.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.